Spinocerebellar Ataxia clinical trials

Explore recruiting spinocerebellar ataxia clinical trials.

Recruiting spinocerebellar ataxia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Spinocerebellar Ataxia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study

Italy, Germany, Austria, Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, doubleblind, placebo-controlled pilot trial with a lead in phase

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

Spain, Portugal, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1

Italy, Poland, Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, parallel-arm, double blind, placebo-controlled study to assess the efficacy of fampridine for patients with spinocerebellar ataxia SCA27B caused by a GAA expansion in the FGF14 gene.(TREAT-FGF14)

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study

Germany, Netherlands, Czechia, Slovakia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Spinocerebellar Ataxia trials by city

Spinocerebellar Ataxia in Toronto Spinocerebellar Ataxia in Vancouver Spinocerebellar Ataxia in Montreal Spinocerebellar Ataxia in Calgary Spinocerebellar Ataxia in Edmonton Spinocerebellar Ataxia in Ottawa Spinocerebellar Ataxia in Winnipeg Spinocerebellar Ataxia in Quebec City Spinocerebellar Ataxia in Hamilton Spinocerebellar Ataxia in Kitchener Spinocerebellar Ataxia in London Spinocerebellar Ataxia in Halifax Spinocerebellar Ataxia in New York Spinocerebellar Ataxia in Los Angeles Spinocerebellar Ataxia in Chicago Spinocerebellar Ataxia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease